Page 215 of 282: studies 2,141 to 2,150 of 2,815, newest first. Back to the LSD overview
Journal of Pastoral Care & Counseling November 13, 2021 F. Gelo
Genre: Documentary Run Time: 1 h 21 min Director Louie Schwartzberg Writer: Mark Monroe Producer: Louie Schwartzberg, Lyn Davis Lear, Elease Lui Stemp I enjoy films that entertain. I relish films that introduce me to a larger world. Above all I prize films that introduce me to the unknown and challenge those powerful interests that evaluate and control the flow of knowledge for their own...
Drug and Alcohol Dependence October 28, 2021 Christopher P Salas-Wright, James C Hodges, Audrey Hang Hai et al.
Background: Roughly one in ten American adults have used hallucinogens, and emerging evidence suggests that the prevalence of use is increasing. However, our understanding of the degree to which individuals "specialize" in the use of a particular hallucinogen or are poly-hallucinogen users remains incomplete. Methods: This study examined data from 6381 individuals reporting past-year...
Brain October 22, 2021 Manoj K. Doss, Maxwell B. Madden, Andrew Gaddis et al. 196 citations
Abstract Classic psychedelic drugs such as psilocybin and lysergic acid diethylamide (LSD) have recaptured the imagination of both science and popular culture, and may have efficacy in treating a wide range of psychiatric disorders. Human and animal studies of psychedelic drug action in the brain have demonstrated the involvement of the serotonin 2A (5-HT2A) receptor and the cerebral cortex in...
Archives of The Medicine and Case Reports October 13, 2021 Andrian Fajar Kusumadewi 2 citations
Introduction. Psilocybe mushroom, or wi dely known as the magic mushroom is a variety of mushroom commonly consumed because of hallucinogenic traits it causes toward its consumer. This hallucinogenic effect is caused by Psilocybin, a hallucinogenic substance often found within Psilocybe mushroom. This substance affects mental state of the consumer and has similar effect to those of LSD and...
CNS Spectrums September 30, 2021 Xénia Gonda, Péter Döme, Joanna C. Neill et al. 77 citations
Abstract Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are several classes of dissimilar antidepressant drugs approved for MDD, the current drugs have either limited efficacy or are associated with undesirable side effects and withdrawal symptoms. The efficacy and side effects of antidepressant drugs are...
Frontiers in Pharmacology September 29, 2021 João Castelhano, Gisela Lima, Marta Teixeira et al. 34 citations
There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by the proposal that they have potential therapeutic benefits, based on their molecular mimicry of serotonin. It is widely believed that they act mainly through 5HT2A receptors but their effects on neural activation of distinct brain systems are not...
TIPS - Trends in Pharmacological Sciences September 24, 2021 Lily R. Aleksandrova, Anthony G. Phillips 255 citations
The emerging therapeutic efficacy of ketamine and classical psychedelics for depression has inspired tremendous interest in the underlying neurobiological mechanisms. We review preclinical and clinical evidence supporting neuroplasticity as a convergent downstream mechanism of action for these novel fast-acting antidepressants. Through their primary glutamate or serotonin receptor targets,...
Frontiers in Pharmacology September 16, 2021 Lukas A Basedow, Thomas Riemer, Simon Reiche et al. 16 citations
Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...
Bulletin of Integrative Psychiatry September 15, 2021 Dan Cătălin Oprea, Loretta Epure, Vasile Chiriță et al.
Psychedelic drugs (also called hallucinogens, psychotogenics, psycholytics, entheogens) are substances that act mainly on the 5-HT2 serotonergic receptor.There are two main groups of psychedelics: indoleamines (lysergic acid diethylamide-LSD, N, N-dimethyltryptamine-DMT, and psilocybin) and phenethylamines (mescaline, dimethoxymethamphetamine-DOM, methylenedioxyamphetamine-MDA, and...
Frontiers in Psychiatry September 10, 2021 Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers 259 citations
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. These substances induce cognitive, antidepressant, anxiolytic, and antiaddictive effects suggested to arise from biological changes similar to conventional antidepressants or the rapid-acting substance ketamine. The proposed route is by inducing brain...